Clinical trials: Cerebral Lesion
Central Nervous System Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.
- Trial name
- NCT00395460
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Magnevist
- Where
- 4 sites in China
- Volunteers
- 147 people
- Sponsor
- Bayer
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Small/Large Bowel
PillCam SB3 Capsule- Feasibility Study
Study hypothesis: PillCam SB3 is a new capsule designed to provide an improved image quality, and improved SB and duodenum tissue coverage due to Adaptive Frame Rate (AFR) of 2-6 fps, which will create more images for evaluation…
- Trial name
- NCT01433042
- Testing
- capsule endoscopy
- Where
- 4 sites in Israel, Romania and 2 more
- Volunteers
- 225 people
- Sponsor
- Medtronic - MITG
Glioblastoma
Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions
This will be an open-label, pilot, exploratory, single centre clinical investigation. This is an early feasibility single arm study. No formal hypothesis is proposed.
- Trial name
- NCT05296122
- Testing
- TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Clinical Laserthermia Systems AB
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.
Mild Traumatic Brain Injury, Intracranial Lesions
TES HT100 Clinical Validation for Brain Injury Screening in Patients With Mild Head Trauma or Neurological Symptoms
The goal of this clinical study is to evaluate how accurately and safely the TES HT100 device can identify intracranial abnormalities in adult emergency department patients with mild head trauma or neurological symptoms that are…
- Conditions
- Mild Traumatic Brain Injury, Intracranial Lesions, Neurological Symptoms Not Related to Head Trauma
- Trial name
- TESCO (NCT07490418)
- Testing
- Temnographic Brain Screening Examination
- Where
- 3 sites in Italy, Poland
- Volunteers
- 850 people
- Sponsor
- B&B srl
Enhancing Brain Lesions
MR Image Synthesis With Low Gadobutrol Dose and AI
Study 22403 is a Phase 1 / Proof of Concept exploratory investigation to assess the non-inferiority of low dose gadobutrol and SubtleGAD™, a software medical device using an Artificial Intelligence (AI) deep learning-based method…
- Trial name
- NCT06224543
- Testing
- SubtleGAD, Gadobutrol
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Subtle Medical
Alzheimer's Disease
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
This is a multicenter study to evaluate the efficacy, safety and tolerability of Rivastigmine patch in patients with mild to moderate Alzheimer's disease switched from Cholinesterase Inhibitors.
- Trial name
- NCT01529619
- Testing
- Rivastigmine transdermal patch
- Where
- 11 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine…
- Trial name
- KAPA (NCT00549601)
- Testing
- Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day)
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Novartis
Brain Tumor
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system.
- Trial name
- NCT00147056
- Testing
- ExAblate transcranial system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- InSightec
Alzheimer's Disease
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a…
- Trial name
- CARE (NCT00731224)
- Testing
- Rivastigmine transdermal patch
- Where
- 40 sites in Australia, Malaysia and 3 more
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
This study is designed to evaluate caregiver preference for Exelon® patch (target patch size 10 cm²) treatment in patients with Alzheimer's disease (MMSE 10-26) who were under cholinesterase inhibitor treatment and experienced…
- Trial name
- BETTER (NCT01047579)
- Testing
- Rivastigmine transdermal
- Where
- 5 sites in Israel
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Carotid Artery Stenosis
Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)(Extended Follow-Up)
Purpose: To assess the long-term safety and efficacy of the intravascular lithotripsy system for pre-treatment of calcified carotid artery stenosis.
- Trial name
- NCT06936189
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma
Carotid Atherosclerosis, Carotid Artery Disease
ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"
1. To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) 2.
- Trial name
- NCT00180518
- Testing
- Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
- Volunteers
- 581 people
- Sponsor
- Abbott Medical Devices
Stroke, Craniocerebral Trauma
Pilot Study Assessing the Feasibility of Treating Foot Drop With the Neurostep™ System.
This pilot feasibility study is assessing the safety and technical performance of the Neurostep™ System for the restoration of independent gait in subjects with gait disorder (i.e. foot drop) secondary to a CNS lesion (e.g.
- Trial name
- NCT00860210
- Testing
- Neurostep™ System
- Where
- 4 sites in Canada, India and 1 more
- Volunteers
- 14 people
- Sponsor
- Neurostream Technologies G.P.
Parkinson's Disease
A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm^2, under the assumption that both patch formulations show similar…
- Trial name
- NCT02230904
- Testing
- Rotigotine (Test product PR 2.3.1), Rotigotine (Reference product PR 2.1.1)
- Where
- 11 sites in Germany
- Volunteers
- 57 people
- Sponsor
- UCB BIOSCIENCES GmbH
Migraine Disorders
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
- Trial name
- NP101-006 (NCT00720018)
- Testing
- NP101 Sumatriptan Iontophoretic Transdermal Patch
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- NuPathe Inc.
Mild to Moderate Alzheimer's Disease
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's…
- Trial name
- ENA1stepswitch (NCT02703636)
- Testing
- Rivastigmine Patch
- Where
- 19 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Cerebrovascular Accident
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke.
- Trial name
- NCT00044070
- Testing
- YM872 (zonampanel)
- Where
- 89 sites in United States, Austria and 4 more
- Sponsor
- Astellas Pharma Inc